Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management

William Virgil Brown, Ira Goldberg, Paul Duell, Daniel Gaudet

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Plasma triglyceride concentrations are normally below 150 mg/dL in the fasting state. However, these lipids can reach values of several thousand mg/dL. Elevations in this range are due to a massive retention of chylomicrons and usually result from multiple genetic variants with superimposed influences such as diabetes and immune disorders. Less commonly, major gene defects in lipoprotein metabolism can be the cause. These may present soon after birth with strong evidence of familial penetrance. The causes of this syndrome have been discussed in a Roundtable published in the most recent issue of this Journal. The polygenic etiology may also have a familial presentation with similar clinical import. The diagnosis and management of these disorders is of importance since they can lead to critical clinical syndromes including death from acute hemorrhagic pancreatitis. The chronic management requires a dedicated medical team and a patient committed to an effective regimen. We are joined in this discussion by Dr P. Barton Duell, University of Oregon Health Sciences Center, and Dr Daniel Gaudet of the Université de Montreal, Montreal, Quebec. All have had extensive personal experience in the diagnosis and management of patients with familial chylomicronemia. This Roundtable was recorded on November 11, 2017, during a meeting of the National Lipid Association in New Orleans, Louisiana.

Original languageEnglish (US)
Pages (from-to)254-263
Number of pages10
JournalJournal of Clinical Lipidology
Volume12
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Hyperlipoproteinemia Type I
Lipids
Chylomicrons
Penetrance
Quebec
Immune System Diseases
Pancreatitis
Lipoproteins
Fasting
Triglycerides
Parturition
Health
Genes

Keywords

  • APO C-III
  • Apolipoprotein
  • Clinical management
  • Hyperchylomicronemia
  • Lipoprotein lipase
  • Triglycerides
  • Volasenorsen

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine

Cite this

Roundtable discussion : Familial chylomicronemia syndrome: Diagnosis and management. / Brown, William Virgil; Goldberg, Ira; Duell, Paul; Gaudet, Daniel.

In: Journal of Clinical Lipidology, Vol. 12, No. 2, 01.03.2018, p. 254-263.

Research output: Contribution to journalReview article

Brown, William Virgil ; Goldberg, Ira ; Duell, Paul ; Gaudet, Daniel. / Roundtable discussion : Familial chylomicronemia syndrome: Diagnosis and management. In: Journal of Clinical Lipidology. 2018 ; Vol. 12, No. 2. pp. 254-263.
@article{7b4b29623f004ad8ad87bc816aba9295,
title = "Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management",
abstract = "Plasma triglyceride concentrations are normally below 150 mg/dL in the fasting state. However, these lipids can reach values of several thousand mg/dL. Elevations in this range are due to a massive retention of chylomicrons and usually result from multiple genetic variants with superimposed influences such as diabetes and immune disorders. Less commonly, major gene defects in lipoprotein metabolism can be the cause. These may present soon after birth with strong evidence of familial penetrance. The causes of this syndrome have been discussed in a Roundtable published in the most recent issue of this Journal. The polygenic etiology may also have a familial presentation with similar clinical import. The diagnosis and management of these disorders is of importance since they can lead to critical clinical syndromes including death from acute hemorrhagic pancreatitis. The chronic management requires a dedicated medical team and a patient committed to an effective regimen. We are joined in this discussion by Dr P. Barton Duell, University of Oregon Health Sciences Center, and Dr Daniel Gaudet of the Universit{\'e} de Montreal, Montreal, Quebec. All have had extensive personal experience in the diagnosis and management of patients with familial chylomicronemia. This Roundtable was recorded on November 11, 2017, during a meeting of the National Lipid Association in New Orleans, Louisiana.",
keywords = "APO C-III, Apolipoprotein, Clinical management, Hyperchylomicronemia, Lipoprotein lipase, Triglycerides, Volasenorsen",
author = "Brown, {William Virgil} and Ira Goldberg and Paul Duell and Daniel Gaudet",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.jacl.2018.02.018",
language = "English (US)",
volume = "12",
pages = "254--263",
journal = "Journal of Clinical Lipidology",
issn = "1933-2874",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Roundtable discussion

T2 - Familial chylomicronemia syndrome: Diagnosis and management

AU - Brown, William Virgil

AU - Goldberg, Ira

AU - Duell, Paul

AU - Gaudet, Daniel

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Plasma triglyceride concentrations are normally below 150 mg/dL in the fasting state. However, these lipids can reach values of several thousand mg/dL. Elevations in this range are due to a massive retention of chylomicrons and usually result from multiple genetic variants with superimposed influences such as diabetes and immune disorders. Less commonly, major gene defects in lipoprotein metabolism can be the cause. These may present soon after birth with strong evidence of familial penetrance. The causes of this syndrome have been discussed in a Roundtable published in the most recent issue of this Journal. The polygenic etiology may also have a familial presentation with similar clinical import. The diagnosis and management of these disorders is of importance since they can lead to critical clinical syndromes including death from acute hemorrhagic pancreatitis. The chronic management requires a dedicated medical team and a patient committed to an effective regimen. We are joined in this discussion by Dr P. Barton Duell, University of Oregon Health Sciences Center, and Dr Daniel Gaudet of the Université de Montreal, Montreal, Quebec. All have had extensive personal experience in the diagnosis and management of patients with familial chylomicronemia. This Roundtable was recorded on November 11, 2017, during a meeting of the National Lipid Association in New Orleans, Louisiana.

AB - Plasma triglyceride concentrations are normally below 150 mg/dL in the fasting state. However, these lipids can reach values of several thousand mg/dL. Elevations in this range are due to a massive retention of chylomicrons and usually result from multiple genetic variants with superimposed influences such as diabetes and immune disorders. Less commonly, major gene defects in lipoprotein metabolism can be the cause. These may present soon after birth with strong evidence of familial penetrance. The causes of this syndrome have been discussed in a Roundtable published in the most recent issue of this Journal. The polygenic etiology may also have a familial presentation with similar clinical import. The diagnosis and management of these disorders is of importance since they can lead to critical clinical syndromes including death from acute hemorrhagic pancreatitis. The chronic management requires a dedicated medical team and a patient committed to an effective regimen. We are joined in this discussion by Dr P. Barton Duell, University of Oregon Health Sciences Center, and Dr Daniel Gaudet of the Université de Montreal, Montreal, Quebec. All have had extensive personal experience in the diagnosis and management of patients with familial chylomicronemia. This Roundtable was recorded on November 11, 2017, during a meeting of the National Lipid Association in New Orleans, Louisiana.

KW - APO C-III

KW - Apolipoprotein

KW - Clinical management

KW - Hyperchylomicronemia

KW - Lipoprotein lipase

KW - Triglycerides

KW - Volasenorsen

UR - http://www.scopus.com/inward/record.url?scp=85043300075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043300075&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2018.02.018

DO - 10.1016/j.jacl.2018.02.018

M3 - Review article

AN - SCOPUS:85043300075

VL - 12

SP - 254

EP - 263

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

SN - 1933-2874

IS - 2

ER -